The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients
Primary Purpose
Osteoarthritis Hand
Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Celecoxib 100 MG
Celecoxib 200mg
Sponsored by

About this trial
This is an interventional treatment trial for Osteoarthritis Hand focused on measuring Osteoarthritis Hand
Eligibility Criteria
Inclusion Criteria:
- Agreement with written informed consent and 19 years of age and older
- Patients history of OA of hand according to ACR criteria
- The 100mm Pain VAS is over 40mm
Exclusion Criteria:
- History of OA of hand surgery
- Intra-articular injections within 3 months
- History of OA of hand infections within 3 months
- Who had taken a drug that has a control of result in clinical trial by investigator's decision
- Pregnant women, nursing mothers or Fertile women who not practice contraception with appropriate methods
- clinically significant hepatic, renal, cardiovascular diseases
- Any history of adverse reaction to the study drugs
- Patients with gastrointestinal ulcers or bleeding disorders
- Finger joint injury within 6 months
Who had following results after examination
- K ≥ 5.5mEq/L
- eGFR ≤ 30ml/min/1.73m^2
- Patients on any other clinical trial or experimental treatment in the past 3 months
- Taking narcotic analgesics or patches
- History of drug abuse or alcoholism
- Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders
- An impossible one who participates in clinical trial by investigator's decision
Sites / Locations
- Soon Chun Hyang University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Celecoxib 100mg
Celecoxib 200mg
Arm Description
Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
Outcomes
Primary Outcome Measures
The change of 100mm Pain VAS score at 6 weeks relative to the baseline value of each group
Secondary Outcome Measures
Changes in each item of K-AUSCAN at 6 weeks relative to the baseline value of each group
The total point change of K-AUSCAN at 6 weeks relative to the baseline value of each group
Total score change of insomnia severity at 6 weeks relative to the baseline value of each group
Total dosing days of acetaminophen for 6 weeks in each group
The total dose of acetaminophen for 6 weeks in each group
Percentage of subjects using acetaminophen for 6 weeks in each group
Full Information
NCT ID
NCT03067194
First Posted
February 3, 2017
Last Updated
January 28, 2020
Sponsor
Chong Kun Dang Pharmaceutical
1. Study Identification
Unique Protocol Identification Number
NCT03067194
Brief Title
The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients
Official Title
Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Celecoxib 200mg Capsule QD and Celecoxib 100mg BID in Hand Osteoarthritis Patients
Study Type
Interventional
2. Study Status
Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
December 27, 2016 (Actual)
Primary Completion Date
July 10, 2017 (Actual)
Study Completion Date
November 20, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate efficacy and safety of Celecoxib capsule in hand osteoarthritis patients.
Detailed Description
This is a six-weeks, open-label, multi-center, randomized study. Patients take Celecoxib 200mg capsule once a day or Celecoxib 100mg capsules twice per day. If patients do not tolerate the pain, they are able to take Acetaminophen as a rescue medication during 6 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis Hand
Keywords
Osteoarthritis Hand
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
117 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Celecoxib 100mg
Arm Type
Active Comparator
Arm Description
Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
Arm Title
Celecoxib 200mg
Arm Type
Active Comparator
Arm Description
Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
Intervention Type
Drug
Intervention Name(s)
Celecoxib 100 MG
Other Intervention Name(s)
Celecoxib 100mg capsule
Intervention Description
Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
Intervention Type
Drug
Intervention Name(s)
Celecoxib 200mg
Other Intervention Name(s)
Celecoxib 200mg capsule
Intervention Description
Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
Primary Outcome Measure Information:
Title
The change of 100mm Pain VAS score at 6 weeks relative to the baseline value of each group
Time Frame
baseline, 6weeks
Secondary Outcome Measure Information:
Title
Changes in each item of K-AUSCAN at 6 weeks relative to the baseline value of each group
Time Frame
baseline, 6weeks
Title
The total point change of K-AUSCAN at 6 weeks relative to the baseline value of each group
Time Frame
baseline, 6weeks
Title
Total score change of insomnia severity at 6 weeks relative to the baseline value of each group
Time Frame
baseline, 6weeks
Title
Total dosing days of acetaminophen for 6 weeks in each group
Time Frame
6weeks
Title
The total dose of acetaminophen for 6 weeks in each group
Time Frame
6weeks
Title
Percentage of subjects using acetaminophen for 6 weeks in each group
Time Frame
6weeks
Other Pre-specified Outcome Measures:
Title
Safety assessed by the incidence of adverse event
Time Frame
up to 6weeks
Title
laboratory test(Hematology test, Blood chemistry test, Urinalysis)
Time Frame
up to 6weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Agreement with written informed consent and 19 years of age and older
Patients history of OA of hand according to ACR criteria
The 100mm Pain VAS is over 40mm
Exclusion Criteria:
History of OA of hand surgery
Intra-articular injections within 3 months
History of OA of hand infections within 3 months
Who had taken a drug that has a control of result in clinical trial by investigator's decision
Pregnant women, nursing mothers or Fertile women who not practice contraception with appropriate methods
clinically significant hepatic, renal, cardiovascular diseases
Any history of adverse reaction to the study drugs
Patients with gastrointestinal ulcers or bleeding disorders
Finger joint injury within 6 months
Who had following results after examination
K ≥ 5.5mEq/L
eGFR ≤ 30ml/min/1.73m^2
Patients on any other clinical trial or experimental treatment in the past 3 months
Taking narcotic analgesics or patches
History of drug abuse or alcoholism
Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders
An impossible one who participates in clinical trial by investigator's decision
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hyun Sook Kim
Organizational Affiliation
Soonchunhyang University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chan Hong Jeon
Organizational Affiliation
Soonchunhyang University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Sung Hae Jang
Organizational Affiliation
Soonchunhyang University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Soon Chun Hyang University Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients
We'll reach out to this number within 24 hrs